Dr. Kraemer’s research explores how protein aggregation contributes to neurodegenerative diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, and frontotemporal degeneration. Dr. Kraemer has developed animal models of the tau pathology seen in Alzheimer’s disease using both transgenic mice and transgenic C. elegans. Dr. Kraemer’s current work focuses on dissecting the genetic requirements for tau mediated neurodegeneration in these models. The approach leverages the experimental advantages of the C. elegans worm to identify genes involved tauopathy and TDP-43 proteinopathy. The role of these newly identified genes will be explored using transgenic mouse models. As new genes are identified that participate in tau and TDP-43 neurotoxicity, potential strategies for preventing neurodegeneration can be tested with the ultimate goal of developing effective therapies for neurodegenerative disorders.
ADRC Research and Education Component
As Co-Lead of the ADRC's Research Education Component (REC), Dr. Kraemer will help oversee the effort to train and develop a community of clinical, basic and translational Alzheimer's disease researchers with the necessary clinical, scientific and technical competence to effectively collaborate to define the mechanistic and biological underpinnings of Alzheimer's and related dementia, and to translate this understanding to improve the lives of those living with memory loss and dementia.
Neurodevelopment & Neurodegeneration, Tissue Injury & Regeneration